Recently, the European Parliament adopted its position on the revision of the EU’s legislative framework on fluorinated greenhouse gases (F-gases) emissions.
Chiesi shares the climate objectives and ambitions of European policymakers and welcomes the robust discussion around the pharmaceutical uses of F-gases, in particular pressurized metered dose inhalers (pMDIs).
As a patient-centered company, we believe that access to the right treatment options is crucial for patients’ well-being. Chiesi is committed to developing innovative solutions that prioritize patient care and choice, while minimizing our environmental impact.
We look forward to the next steps of the legislative process to confirm an approach that keeps the EU level of climate ambition, and factors in the unpredictability of pharmaceutical development and the uncertainties of the regulatory approval process for medical products – so as not to compromise patient care and choice and ensure a smooth transition to carbon minimal alternatives.
As a Benefit Corporation and a certified B Corp, our actions reflect the principle of shared value which guides us: the creation of value not only for our patients and customers, but also for society and the planet.
We will continue to engage with policymakers around Europe to reduce our own impact and contribute to the climate objectives of the industry as a whole.